Cogent Biosciences, Inc.
COGTNASDAQHealthcare● Active
$31.14
+$0.12(+0.38%)
Market Cap$5.3B
P/E Ratio—
52W High$43.73
52W Low$5.485
Cogent Biosciences, Inc. (COGT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
COGT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.53
Est. -$0.53 · +0.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
COGT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.55 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 5, 2026 | -$0.53 | -$0.53 | +0.0% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 17, 2026 | -$0.51 | -$0.55 | -7.8% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.54 | -$0.50 | +7.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.55 | -$0.53 | +3.6% | — | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.56 | -$0.52 | +7.1% | — | — | — |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$0.59 | -$0.09 | +84.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.55 | -$0.64 | -16.4% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.55
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
-$0.53
EPS Est.
-$0.53
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
-$0.55
EPS Est.
-$0.51
EPS Surpr.
-7.8%
Revenue
—
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.54
EPS Surpr.
+7.4%
Revenue
—
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.53
EPS Est.
-$0.55
EPS Surpr.
+3.6%
Revenue
—
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.52
EPS Est.
-$0.56
EPS Surpr.
+7.1%
Revenue
—
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.59
EPS Surpr.
+84.8%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.64
EPS Est.
-$0.55
EPS Surpr.
-16.4%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.95 | $0.95 | $0.95 | 6 |
| Q3 FY2029 | $0.75 | $0.75 | $0.75 | 3 |
| Q2 FY2029 | $0.57 | $0.57 | $0.57 | 5 |
| Q1 FY2029 | $0.41 | $0.41 | $0.41 | 3 |
| Q4 FY2028 | $0.25 | $0.25 | $0.25 | 7 |
| Q3 FY2028 | $0.09 | $0.09 | $0.09 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.4B | $0.4B | $0.4B | 11 |
| Q3 FY2029 | $0.4B | $0.4B | $0.4B | 10 |
| Q2 FY2029 | $0.3B | $0.3B | $0.3B | 10 |
| Q1 FY2029 | $0.3B | $0.3B | $0.3B | 11 |
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 6 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +0.0% | $36.73 | $36.98 | +0.68% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -7.8% | $36.53 | $37.62 | +2.98% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +7.4% | $14.72 | $14.82 | +0.68% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +3.6% | $12.05 | $11.36 | -5.73% |
| ▲ Q2 FY2025 | May 6, 2025 | +7.1% | $5.57 | $4.70 | -15.62% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +84.8% | $7.46 | $6.99 | -6.30% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -16.4% | $10.40 | $10.38 | -0.19% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -7.3% | $9.14 | $9.26 | +1.31% |
Q2 FY2026+0.68%
Report Date
May 5, 2026
EPS Beat/Miss
+0.0%
Price Before
$36.73
Price After
$36.98
Q1 FY2026+2.98%
Report Date
Feb 17, 2026
EPS Beat/Miss
-7.8%
Price Before
$36.53
Price After
$37.62
Q4 FY2025+0.68%
Report Date
Nov 7, 2025
EPS Beat/Miss
+7.4%
Price Before
$14.72
Price After
$14.82
Q3 FY2025-5.73%
Report Date
Aug 5, 2025
EPS Beat/Miss
+3.6%
Price Before
$12.05
Price After
$11.36
Q2 FY2025-15.62%
Report Date
May 6, 2025
EPS Beat/Miss
+7.1%
Price Before
$5.57
Price After
$4.70
Q1 FY2025-6.30%
Report Date
Feb 25, 2025
EPS Beat/Miss
+84.8%
Price Before
$7.46
Price After
$6.99
Q4 FY2024-0.19%
Report Date
Nov 12, 2024
EPS Beat/Miss
-16.4%
Price Before
$10.40
Price After
$10.38
Q3 FY2024+1.31%
Report Date
Aug 6, 2024
EPS Beat/Miss
-7.3%
Price Before
$9.14
Price After
$9.26
Avg Beat Reaction-5.26%
Avg Miss Reaction+1.37%
Beat Rate5 / 8 quarters
Largest Move-15.62% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: COGT ends December
Cogent Biosciences, Inc. (COGT) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.53 (in line with the analyst consensus of $-0.53). The next COGT earnings date is expected around September 1, 2026.
Each quarter, investors track COGT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. COGT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
COGT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
COGT earnings · 4 questionsCogent Biosciences, Inc.'s next earnings report is expected around September 1, 2026. COGT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; COGT historically reports after market close (AMC).
COGT earnings datewhen is COGT earningsCOGT next earnings datewhen does COGT report earningsCOGT earnings calendar
▸ Source: FMP · Cogent Biosciences, Inc. SEC filings · US GAAP · Cogent Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026